Inhibition of transcription elongation by the VHL tumor suppressor protein
- PMID: 7660122
- DOI: 10.1126/science.7660122
Inhibition of transcription elongation by the VHL tumor suppressor protein
Abstract
Germline mutations in the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of tumors, including renal carcinoma, hemangioblastoma of the central nervous system, and pheochromocytoma. Here, a cellular transcription factor, Elongin (SIII), is identified as a functional target of the VHL protein. Elongin (SIII) is a heterotrimer consisting of a transcriptionally active subunit (A) and two regulatory subunits (B and C) that activate transcription elongation by RNA polymerase II. The VHL protein was shown to bind tightly and specifically to the Elongin B and C subunits and to inhibit Elongin (SIII) transcriptional activity in vitro. These findings reveal a potentially important transcriptional regulatory network in which the VHL protein may play a key role.
Comment in
-
Tumor suppression and transcription elongation: the dire consequences of changing partners.Science. 1995 Sep 8;269(5229):1400-1. doi: 10.1126/science.7660121. Science. 1995. PMID: 7660121 No abstract available.
Similar articles
-
Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II.Science. 1995 Sep 8;269(5229):1439-43. doi: 10.1126/science.7660129. Science. 1995. PMID: 7660129
-
Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.J Biol Chem. 1997 Oct 24;272(43):27444-9. doi: 10.1074/jbc.272.43.27444. J Biol Chem. 1997. PMID: 9341197
-
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.Science. 1995 Sep 8;269(5229):1444-6. doi: 10.1126/science.7660130. Science. 1995. PMID: 7660130
-
The von Hippel-Lindau tumor suppressor protein.Curr Opin Genet Dev. 2001 Feb;11(1):27-34. doi: 10.1016/s0959-437x(00)00152-0. Curr Opin Genet Dev. 2001. PMID: 11163147 Review.
-
The von Hippel-Lindau tumour suppressor protein: new perspectives.Mol Med Today. 1999 Jun;5(6):257-63. doi: 10.1016/s1357-4310(99)01481-1. Mol Med Today. 1999. PMID: 10366821 Review.
Cited by
-
Therapeutic Strategies for Hereditary Kidney Cancer.Curr Oncol Rep. 2016 Aug;18(8):50. doi: 10.1007/s11912-016-0537-6. Curr Oncol Rep. 2016. PMID: 27325049 Review.
-
The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.Semin Cell Dev Biol. 2005 Aug-Oct;16(4-5):564-74. doi: 10.1016/j.semcdb.2005.03.006. Epub 2005 Apr 26. Semin Cell Dev Biol. 2005. PMID: 15908240 Free PMC article. Review.
-
Enhanced performance of gene expression predictive models with protein-mediated spatial chromatin interactions.Sci Rep. 2023 Jul 20;13(1):11693. doi: 10.1038/s41598-023-38865-5. Sci Rep. 2023. PMID: 37474564 Free PMC article.
-
A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8817-22. doi: 10.1073/pnas.95.15.8817. Proc Natl Acad Sci U S A. 1998. PMID: 9671762 Free PMC article.
-
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10589-94. doi: 10.1073/pnas.93.20.10589. Proc Natl Acad Sci U S A. 1996. PMID: 8855222 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases